I
IX Biopharma Ltd
SGX:42C
IX Biopharma Ltd
SGX:42C
Price:
0.043 SGD
-10.42%
Market Closed
Updated:
May 8, 2024
IX Biopharma Ltd
Operating Income
|
IX Biopharma Ltd
Operating Income Peer Comparison
Comparables:
WVE
H02
H
1J5
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
I
|
IX Biopharma Ltd
SGX:42C
|
Operating Income
-S$6.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
Operating Income
-$68m
|
CAGR 3-Years
24%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Haw Par Corporation Ltd
SGX:H02
|
Operating Income
S$65.3m
|
CAGR 3-Years
53%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
5%
|
|
H
|
Hyphens Pharma International Ltd
SGX:1J5
|
Operating Income
S$12.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
See Also
What is IX Biopharma Ltd's Operating Income?
Operating Income
-6.6m
SGD
-6.6m
SGD
Based on the financial report for Dec 31, 2023, IX Biopharma Ltd's Operating Income amounts to -6.6m SGD.
What is IX Biopharma Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
15%
15%
Over the last year, the Operating Income growth was 30%. The average annual Operating Income growth rates for IX Biopharma Ltd have been 4% over the past three years , 15% over the past five years .
You don't have any saved screeners yet
